Short answer
Nkarta, Inc. (NKTX) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). NKX019 initial clinical data released for myositis and systemic sclerosis from the Ntrust trial program.
Nkarta, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- NKX019 initial clinical data released for myositis and systemic sclerosis from the Ntrust trial program
- Data presented at ACR Convergence 2026, providing an external clinical validation forum
- Investor webcast and presentation disclosed on November 9, 2026, with materials in Exhibits 99.1 and 99.2
Item 8.01 · Other Events
- Preliminary NKX019 efficacy signal in myositis: 5/6 patients, 83%, achieved moderate or major responses at 4 billion cells per dose
- Systemic sclerosis results stronger at 4 billion cells: 6/7 patients, 86%, reached rCRISS-25 response or greater by Day 90
- Safety profile favorable across 40 patients: no deaths, treatment discontinuations, CRS, neurotoxicity, hemophagocytic syndrome or graft-versus-host disease
- Development acceleration: dosing amended to Days 0, 2 and 4, with planned evaluation of 6 billion cells per dose
- Key catalyst: additional follow-up and registrational dose-selection plans expected in the first half of 2027
Item EX-99.1 · Exhibit EX-99.1
- Preliminary NKX019 data support clinical activity in refractory autoimmune disease, strengthening Nkarta’s lead program ahead of regulatory discussions
- Myositis: 5/6 patients achieved moderate or major responses at 4 billion cells per dose, including one sustained TIS 90 response at six months
- Systemic sclerosis: 6/7 achieved rCRISS-25 or greater, with 5/7 reaching rCRISS-50 or greater by Day 90
- Safety profile favorable across 40 patients, with no CRS, ICANS, IEC-HS, GvHD, deaths or adverse-event discontinuations
- Development advancing toward registration: compressed Days 0, 2 and 4 dosing, planned 6 billion-cell evaluation and FDA pathway discussions
Item EX-99.2 · Exhibit EX-99.2
- NKX019 4B-dose cohort showed 5/6 myositis patients with moderate-to-major TIS responses after ≥3 months
- Systemic sclerosis results: 6/7 achieved rCRISS-25 and 5/7 achieved rCRISS-50 by Day 90
- Safety favorable across 40 patients, with no CRS, ICANS, IEC-HS, or GVHD and no treatment discontinuations or deaths
- $216 million cash, cash equivalents and investments as of September 30, 2026, supporting expected runway into 2029
- Key catalysts: FDA registrational-path discussions, 1H 2027 follow-up data, and 4B versus 6B dose selection
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Nkarta, Inc. 8-K filings
Get the next NKTX 8-K as it lands
Follow NKTX for push alerts, or ask the research agent what this filing means.